Cytogenetic and FISH analyses in five patients with hypoplastic bone marrow TO 
THE EDITOR
The differential diagnosis between 'true' SAA and hypoplastic MDS is often difficult because of a reduced bone marrow cellularity.
1,2 Fundamental discriminant clues can be provided by trephine biopsy and by the identification of a chromosome aberration, 3 that, however, has been reported in SAA patients too.
We report on five patients, aged 20-59 years, observed at our Institution between March 1989 and August 1995. Their main clinicohematological characteristics are listed in Table 1 . Cytogenetics and FISH results are reported in Table 2 . At diagnosis an initial cytogenetic analysis showed a normal chromosome pattern in all the patients. All of them evolved into AML showing clonal karyotype defects described according to ISCN 4 (trisomies and monosomies were considered clonal when present in at least two and three metaphases, respectively). We decided to employ FISH retrospectively in order to establish if any minor subclone, carrying the chromosome abnormality detected by cytogenetics at the time of AML transformation, was already present at diagnosis. In order to reinforce the interphase FISH analysis of small subpopulations of cells we decided to apply the probe discovering the clonal chromosome defect along with an additional probe used as an internal control (dual-color FISH). All probes were commercially obtained (Oncor, Gaithersburg, MD, USA).
The digoxygenated 5q31 DNA probe was applied to metaphase cells only along with the 5␣ probe. Its cut-off value was obtained by screening 1000 mitoses from 10 normal controls. We determined the one-sided 95% confidence limit using a binomial distribution for the proportion of metaphase cells that were normal or that carried the del(5)(q13q31). We detected the probability of discovering 0, 1, 2, 3 cells with del(5)(q13q31) by using the upper boundary of the 95% confidence interval. 5 As in normal subjects, 3 was the highest number of cells lacking the 5q31DNA probe signal, probably because of a hybridization failure, the normal range for the cells with this karyotypic defect was fixed at 0.8%.
Monosomy 7 or trisomy 8 or other numerical defects were considered clonal by metaphase and interphase FISH when the percentages of the cells with such abnormalities were above the cut-off value determined for each numerical change. The cut-off value was obtained by screening 25 mitoses and 200 interphase cells from 10 normal controls. Monosomy 7 cut-off was determined by applying the 7␣ probe together with a 12␣ probe. We calculated the mean percentage of mitoses or cells showing two spots due to the internal control and only one spot due to the 7␣ probe plus three times the standard deviation. Monosomy 7 cut-off value for metaphase FISH was 8%; that for interphase FISH was 5%. Trisomy 4 and 8 cut-offs were obtained in the same way and were fixed at 0% for both the numerical defects when considering mitoses, at 2.3% and at 2.5%, respectively, when examining interphase cells.
Despite the high interphase FISH cut-offs for monosomies and trisomies making the identification of minor subclones marked by such abnormalities difficult, this technique succeeded in demonstrating that the clonal defect was already present at disease onset in a few interphase cells obtained from four of our patients (Nos 1, 2, 4 and 5). This result was confirmed by metaphase FISH, that detected similar percentages of clonogenic cells in the same patients, suggesting that, initially, the chromosome defect was really present in a small subpop- ulation of cells. Moreover, a careful review of the karyotypes, obtained at disease onset and considered normal on an initial conventional cytogenetics investigation, demonstrated that few mitoses of the same four patients carried the clonal abnormalities observed on leukemic transformation and retrospectively identified by FISH. These cytogenetics and FISH results might be explained by the very small size of the abnormal clone and not by the low mitotic rate with poor quality metaphases often observed in patients with hypoplastic marrows. In both situations, however, FISH plays an important role in identifying clonogenic cells that may easily escape cytogenetic detection.
An intriguing point in patients with hypocellular marrow is the differential diagnosis between 'true' SAA and hypoplastic MDS. [1] [2] [3] In our patients FISH alone was unable to discriminate between true SAA and hypoplastic MDS, as the presence of a chromosome abnormality per se does not help to make a discriminatory diagnosis. However, karyotypic defects such as monosomy 7, trisomy 8 and sporadically trisomy 6 have been observed in SAA evolving into MDS or into AML. 3 Therefore, an overlap between SAA and MDS may actually exist. 2 This possibility is further illustrated by our patient No. 5, who showed an abnormality identifying a particular subgroup of MDS with a very low probability of evolving into AML, ie a del(5)(q13q31), accompanied by an increased marrow reticulin on trephine biopsy, a sign predictive of AML evolution. 1 This case initially classified as hypo-MDS ultimately developed into AML-M4 88 months after initial diagnosis.
In conclusion, the present FISH study was made possible by conventional cytogenetics, the only reason that the abnormalities present in each case were known. Cytogenetics and FISH were complementary; the latter succeeded in discovering minor subclones at diagnosis and, demonstrating their expansion, it was able to predict AML transformation.
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